327 related articles for article (PubMed ID: 25575713)
21. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.
Ayari C; LaRue H; Hovington H; Caron A; Bergeron A; Têtu B; Fradet V; Fradet Y
Hum Pathol; 2013 Aug; 44(8):1630-7. PubMed ID: 23574787
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
Massari F; Bria E; Ciccarese C; Munari E; Modena A; Zambonin V; Sperduti I; Artibani W; Cheng L; Martignoni G; Tortora G; Brunelli M
PLoS One; 2015; 10(6):e0127908. PubMed ID: 26046361
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.
Ke HL; Chang LL; Yang SF; Lin HH; Li CC; Wu DC; Wu WJ
Urol Oncol; 2011; 29(6):703-9. PubMed ID: 20022267
[TBL] [Abstract][Full Text] [Related]
24. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
25. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
26. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
27. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
Hau AM; Leivo MZ; Gilder AS; Hu JJ; Gonias SL; Hansel DE
Cell Signal; 2017 Jan; 29():96-106. PubMed ID: 27777073
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
[TBL] [Abstract][Full Text] [Related]
29. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
[TBL] [Abstract][Full Text] [Related]
30. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
31. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
32. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
33. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
34. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.
El-Kott AF; Khalil AM; El-Kenawy Ael-M
Int Urol Nephrol; 2004; 36(3):417-23. PubMed ID: 15783118
[TBL] [Abstract][Full Text] [Related]
36. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
37. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.
Illemann M; Laerum OD; Hasselby JP; Thurison T; Høyer-Hansen G; Nielsen HJ; ; Christensen IJ
Cancer Med; 2014 Aug; 3(4):855-64. PubMed ID: 24889870
[TBL] [Abstract][Full Text] [Related]
38. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
[TBL] [Abstract][Full Text] [Related]
39. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
40. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]